undamentalytics Newsletter
Sign in

Viking Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Viking Therapeutics, Inc. had return on equity of -47.3%, debt equal to 0.0% of equity and a current ratio of 9.33. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Return on equity——−175.7%−191.4%−14.2%−9.0%−15.1%−24.6%−39.7%−34.8%−17.9%−47.3%−102.2%
Return on assets−719.1%−253.3%−98.3%−112.3%−13.6%−8.8%−14.6%−23.5%−36.3%−32.0%−17.2%−44.3%−74.1%
Current ratio0.037.692.162.5266.4041.8321.1123.987.6119.1933.099.337.27
Debt to equity—24.7%——0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%42.6%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 6 checks passed · September 30, 2026
What it owns · $977m
Short-term assets $973mLonger-term assets $4m
What it owes, and who funded it · $977m
Short-term liabilities $134mLonger-term liabilities $255mShareholders' equity $589m
  • Short-term assets cover short-term liabilities $973m of assets due within a year against $134m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $973m short-term assets against $255m of longer-dated liabilities.
  • More cash than debt $678m of cash against $251m of debt.
  • Debt below 40% of shareholders' equity Debt is 43% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$463m of operating cash flow against $251m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Viking Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Viking Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viking Therapeutics, Inc.